Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

To study a new investigational treatment for people with advanced non-small cell lung cancer that has a specific EGFR gene change and has continued to grow despite prior targeted therapy. This study compares an investigational medication called Izalontamab Brengitecan with standard platinum-based chemotherapy to see how well each approach works and how safe it is. The goal of the study is to better understand whether the investigational treatment might improve cancer control in this setting.

• Adults 18+ years of age
• Diagnosed with non-squamous non-small cell lung cancer (NSCLC) that has an EGFR mutation and cannot be cured with surgery
• Cancer has worsened after treatment with a third-generation EGFR-targeted therapy
• Able to receive platinum-based chemotherapy

• Infusions or drug administration
• Regular treatment visits
• Monitoring for side effects and cancer response